Johnson & Johnson's SPRAVATO® (esketamine) Approved Monotherapy for Treatment-Resistant Depression
Wednesday, January 22, 2025
Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray.
TRD is characterised by a lack of adequate response to at least two oral antidepressants. This condition affects a significant portion of individuals with MDD, often necessitating alternative treatment approaches. Conventional therapies may take weeks to show efficacy, leaving patients with limited options for timely relief.
SPRAVATO® (esketamine) nasal spray is approved for adults with TRD or depressive symptoms associated with acute suicidal ideation or behaviour. It can be used as a standalone treatment or in combination with an oral antidepressant.
By targeting the glutamate pathway, SPRAVATO® offers a unique approach to addressing depressive symptoms, providing faster relief and reducing the risk of relapse for many patients.
This approval establishes SPRAVATO® as the first and only monotherapy specifically for adults with major depressive disorder (MDD) who have not achieved adequate relief from at least two oral antidepressants.
SPRAVATO® is administered via a nasal spray and acts on the brain's glutamate pathway, offering a novel mechanism of action distinct from conventional antidepressants.
Its use is subject to a restricted program, the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS), due to potential risks such as sedation, dissociation, and misuse.
MDD impacts approximately 21 million adults in the United States, with one-third not responding to oral antidepressants. Treatment-resistant depression (TRD), a challenging subset of MDD, has significant implications for patients' quality of life and imposes a substantial economic burden.
Improvements were observed as early as 24 hours, with sustained benefits through 28 days. Remission rates at four weeks were notably higher among patients treated with SPRAVATO® compared to those receiving a placebo.
The approval follows robust clinical trials demonstrating that SPRAVATO® provides rapid and effective symptom relief.
Source: jnj.com
